FDA panel against use of Avastin for breast cancer

A panel of cancer experts ruled Wednesday that Avastin - the world's best-selling cancer drug, developed by Genentech in South San Francisco - should no longer be used in breast cancer patients because of concerns the medicine didn't work as well in follow-up studies and may cause deadly bleeding.Outside advisers to the Food and Drug Administration voted 6-0 against Avastin's use in breast cancer